Latest Director Appointments News

Platinum Asset Management has finalized its merger with L1 Capital, issuing over 1.65 billion new shares and announcing a rebrand to L1 Group Limited alongside significant board changes and share escrow arrangements.

EMU NL’s securities have been suspended from ASX trading due to a failure to maintain the minimum number of directors required by law. The suspension highlights governance challenges and raises questions about the company’s path to compliance.

Gold Mountain Limited launches a $3.5 million capital raise through an entitlement offer and placement to fund exploration projects in Brazil and Papua New Guinea, supported by key shareholders including Jose Luis Manzano.

Webjet Group Limited has received a shareholder requisition backed by significant investors seeking to appoint new directors and remove recent board appointees, signaling potential shifts in company governance.

Gumtree Australia Markets has officially appointed Tommy Logtenberg as Managing Director, cementing his leadership role after serving as CEO since 2023. The move signals continuity and confidence in the company’s strategic direction.

InVert Graphite has appointed Andrew Lawson as Managing Director following his initial CEO tenure, signaling confidence in his leadership as the company advances its critical minerals projects.

The Takeovers Panel has amended its orders for Emu NL’s upcoming general meeting, removing the resolution to elect Keith Rowe as a director after his withdrawal. This latest variation continues a complex saga of boardroom changes at Emu NL.

Peninsula Energy has updated its prospectus to announce the appointment of Tejal Magan as a Non-executive Director, enhancing its governance ahead of ongoing equity offers.

Camplify Holdings has responded to ASX concerns over a delayed director interest notice, revealing internal process failures and promising tighter compliance measures.

News Corporation’s Murdoch Family Trust is selling 14.2 million Class B shares in a significant secondary offering, marking a pivotal step in a broader ownership restructuring that reshapes voting control and family interests.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.